Cancer Drug Can Activate HIV Reservoirs To Target For Eradication

Dr. Satya Dandekar PhD Professor and Chair Department of Medical Microbiology and Immunology UC Interview with:
Dr. Satya Dandekar PhD
Professor and Chair
Department of Medical Microbiology and Immunology
UC Davis

Medical Research: What is the background for this study? What are the main findings?

Dr. Dandekar: Current anti-retroviral therapy is effective in suppressing HIV replication and enhancing immune functions in HIV infected individuals. However, it fails to eradicate the latent HIV reservoirs. Therapy interruption leads to a rapid viral rebound in these patients.  Eradication of latent HIV reservoirs is essential to achieve HIV cure. A “shock and kill” strategy for HIV cure has been proposed that involves reactivation of latent viral reservoirs using latency reversal agents (LRA) and eradication by the immune response. This highlights the need to identify potent LRAs to optimally activate latent HIV reservoirs so that immune surveillance and clearance mechanisms can be effectively engaged in the process of viral eradication. We have found that ingenol-3-angelate (PEP005), an anti-cancer drug can effectively reactivate latent HIV. It is a protein kinase C agonist that activates NF-kB and stimulates HIV expression. In combination with another compound, JQ1, a previously known p-TEFb agonist, the efficacy of PEP005 for HIV reactivation is markedly increased. In addition, ingenol-3-angelate decreases the expression of HIV co-receptors on immune cells, which potentially will help preventing further spread of the virus. The use of ingenol-3-angelate in combination with other latency reversal agents provides an excellent opportunity to optimally activate latent HIV reservoirs and target them for eradication.

Medical Research: What should clinicians and patients take away from your report?

Dr. Dandekar: With the availability of suppressive anti-retroviral therapy, it is now possible to explore innovative approaches for HIV eradication.  Identification of potent latency reversal agents and optimization of the combination of LRAs will be important to achieve full activation of the latent HIV reservoirs.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Dandekar: Ingenol-3-angelate is a potential candidate for advancing to clinical HIV cure studies based on its ability to activate latent HIV, act synergistically with other candidate LRAs and to potentially protect immune targets by down-modulation of HIV co-receptor expression.  Future studies can be focused on pharmacokinetic evaluations in vivo and proof of concept experiments in the experimental models.


Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

 Guochun Jiang, Erica A. Mendes, Philipp Kaiser, Daniel P. Wong, Yuyang Tang, Ivy Cai, Anne Fenton, Gregory P. Melcher, James E. K. Hildreth, George R. Thompson, Joseph K. Wong, Satya Dandekar is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional.

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Dr. Satya Dandekar PhD (2015). Cancer Drug Can Activate HIV Reservoirs To Target For Eradication 

Last Updated on July 31, 2015 by Marie Benz MD FAAD